Back

Very short-term effects of single dose of proprotein convertase subtilisin kexin 9 inhibitor therapy before percutaneous coronary intervention

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: All things percutaneous coronary intervention: a potpourri of percutaneous coronary intervention-related topics Intracoronary Ultrasound ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tatsuhiro Kataoka

Fukui University Hospital, Fukui (Japan)

9 More presentations in this session

Presentation thumbnail
Examining prognostic scores for short-term major adverse cardiovascular events prediction following primary PCI: a comparative analysis
Doctor U. Safdar (Karachi, PK)
Abstract Slides Video
Presentation thumbnail
Both fibrosis-4 index and fibrosis-5 index can predict the prognosis of patients after percutaneous coronary intervention
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Optimizing elective high-risk PCI with ECMO support: the value of completely percutaneous use of VA-ECMO
Mr A. Griffioen (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of moderate to severe anemia on clinical outcomes in patients with atrial fibrillation and coronary artery disease requiring percutaneous coronary intervention
Miss K. Abe (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
Assessment of safety, efficacy and learning curve of intravascular lithotripsy in real world practice within a high volume calcium modification centre
Doctor J. Hinton (Bournemouth, GB)
Abstract Slides Video

Access the full session

Session thumbnail
All things percutaneous coronary intervention: a potpourri of percutaneous coronary intervention-related topics

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibitors and coronary atherosclerotic plaque modification: a meta-analysis
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis
thumbnail
Congress Presentation
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources